Aberrant signaling of EGFR due to overexpression or somatic mutations—amino acid replacements, deletions or insertions—has suggested a role for EGFR in many types of human cancers, the most common cancer being non-small cell lung cancer (NSCLC) [17,18,19,20]. Here, EGFR is linked to non-small cell lung carcinoma.